Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Aug;80(11):1689–1696. doi: 10.1038/sj.bjc.6690585

Fractionated γ-irradiation renders tumour cells more responsive to apoptotic signals through CD95

M A Sheard 1, P H Krammer 2, J Zaloudik 1
PMCID: PMC2363128  PMID: 10468284

Abstract

Signals through the CD95 surface receptor can specifically induce apoptosis. Some tumour cell lines are sensitive to CD95 signals, and insensitive cells can be converted to a sensitive phenotype if given appropriate treatment. To determine whether the apoptotic response of tumour cells to signalling through CD95 might be enhanced by ionizing irradiation, carcinoma cells were treated with either single-dose or fractionated γ-irradiation. The response to treatment with an agonist anti-CD95 antibody was enhanced by pretreatment with either a single large dose or daily fractionated radiation. Fractionated irradiation induced cumulative and prolonged up-regulation of CD95 expression in cell lines bearing functional p53. Since two of four cell lines exhibiting heightened responsiveness to CD95-mediated signals following fractionated irradiation express mutant p53 and displayed little or no up-regulation of CD95, enhanced responsiveness did not correlate with p53 status and CD95 up-regulation. Continuous inhibition of CD95/CD95–ligand interactions during fractionated irradiation provided no protective effect to cells, arguing that autologous CD95/CD95–ligand interactions did not contribute to the direct lethal effect of irradiation. We conclude that fractionated γ-irradiation provides an extended period of time when carcinoma cells are more responsive to CD95-mediated signals in vitro. © 1999 Cancer Research Campaign

Keywords: CD95, apoptosis, ionizing radiation, carcinoma, p53

Full Text

The Full Text of this article is available as a PDF (405.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashkenas J., Werb Z. Proteolysis and the biochemistry of life-or-death decisions. J Exp Med. 1996 May 1;183(5):1947–1951. doi: 10.1084/jem.183.5.1947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Clarke A. R., Purdie C. A., Harrison D. J., Morris R. G., Bird C. C., Hooper M. L., Wyllie A. H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 1993 Apr 29;362(6423):849–852. doi: 10.1038/362849a0. [DOI] [PubMed] [Google Scholar]
  3. Dhein J., Walczak H., Bäumler C., Debatin K. M., Krammer P. H. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) Nature. 1995 Feb 2;373(6513):438–441. doi: 10.1038/373438a0. [DOI] [PubMed] [Google Scholar]
  4. Eischen C. M., Kottke T. J., Martins L. M., Basi G. S., Tung J. S., Earnshaw W. C., Leibson P. J., Kaufmann S. H. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood. 1997 Aug 1;90(3):935–943. [PubMed] [Google Scholar]
  5. Eischen C. M., Schilling J. D., Lynch D. H., Krammer P. H., Leibson P. J. Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis. J Immunol. 1996 Apr 15;156(8):2693–2699. [PubMed] [Google Scholar]
  6. Friesen C., Herr I., Krammer P. H., Debatin K. M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med. 1996 May;2(5):574–577. doi: 10.1038/nm0596-574. [DOI] [PubMed] [Google Scholar]
  7. Fulda S., Sieverts H., Friesen C., Herr I., Debatin K. M. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 1997 Sep 1;57(17):3823–3829. [PubMed] [Google Scholar]
  8. Graham M. L., 2nd, Dalquist K. E., Horwitz K. B. Simultaneous measurement of progesterone receptors and DNA indices by flow cytometry: analysis of breast cancer cell mixtures and genetic instability of the T47D line. Cancer Res. 1989 Jul 15;49(14):3943–3949. [PubMed] [Google Scholar]
  9. Haimovitz-Friedman A., Kan C. C., Ehleiter D., Persaud R. S., McLoughlin M., Fuks Z., Kolesnick R. N. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med. 1994 Aug 1;180(2):525–535. doi: 10.1084/jem.180.2.525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Herr I., Wilhelm D., Böhler T., Angel P., Debatin K. M. Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBO J. 1997 Oct 15;16(20):6200–6208. doi: 10.1093/emboj/16.20.6200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., Bodmer J. L., Schröter M., Burns K., Mattmann C. Inhibition of death receptor signals by cellular FLIP. Nature. 1997 Jul 10;388(6638):190–195. doi: 10.1038/40657. [DOI] [PubMed] [Google Scholar]
  12. Jättelä M., Benedict M., Tewari M., Shayman J. A., Dixit V. M. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene. 1995 Jun 15;10(12):2297–2305. [PubMed] [Google Scholar]
  13. Krammer P. H., Dhein J., Walczak H., Behrmann I., Mariani S., Matiba B., Fath M., Daniel P. T., Knipping E., Westendorp M. O. The role of APO-1-mediated apoptosis in the immune system. Immunol Rev. 1994 Dec;142:175–191. doi: 10.1111/j.1600-065x.1994.tb00889.x. [DOI] [PubMed] [Google Scholar]
  14. Landowski T. H., Gleason-Guzman M. C., Dalton W. S. Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood. 1997 Mar 15;89(6):1854–1861. [PubMed] [Google Scholar]
  15. Landowski T. H., Qu N., Buyuksal I., Painter J. S., Dalton W. S. Mutations in the Fas antigen in patients with multiple myeloma. Blood. 1997 Dec 1;90(11):4266–4270. [PubMed] [Google Scholar]
  16. Lichter A. S., Lawrence T. S. Recent advances in radiation oncology. N Engl J Med. 1995 Feb 9;332(6):371–379. doi: 10.1056/NEJM199502093320607. [DOI] [PubMed] [Google Scholar]
  17. Lowe S. W., Schmitt E. M., Smith S. W., Osborne B. A., Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 1993 Apr 29;362(6423):847–849. doi: 10.1038/362847a0. [DOI] [PubMed] [Google Scholar]
  18. Lu X., Lane D. P. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell. 1993 Nov 19;75(4):765–778. doi: 10.1016/0092-8674(93)90496-d. [DOI] [PubMed] [Google Scholar]
  19. Martinez-Lorenzo M. J., Gamen S., Etxeberria J., Lasierra P., Larrad L., Piñeiro A., Anel A., Naval J., Alava M. A. Resistance to apoptosis correlates with a highly proliferative phenotype and loss of Fas and CPP32 (caspase-3) expression in human leukemia cells. Int J Cancer. 1998 Jan 30;75(3):473–481. doi: 10.1002/(sici)1097-0215(19980130)75:3<473::aid-ijc23>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  20. Mori S., Jewett A., Murakami-Mori K., Cavalcanti M., Bonavida B. The participation of the Fas-mediated cytotoxic pathway by natural killer cells is tumor-cell-dependent. Cancer Immunol Immunother. 1997 Jul;44(5):282–290. doi: 10.1007/s002620050384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Müller M., Strand S., Hug H., Heinemann E. M., Walczak H., Hofmann W. J., Stremmel W., Krammer P. H., Galle P. R. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest. 1997 Feb 1;99(3):403–413. doi: 10.1172/JCI119174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Nagata S. Apoptosis by death factor. Cell. 1997 Feb 7;88(3):355–365. doi: 10.1016/s0092-8674(00)81874-7. [DOI] [PubMed] [Google Scholar]
  23. Oshimi Y., Oda S., Honda Y., Nagata S., Miyazaki S. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. J Immunol. 1996 Oct 1;157(7):2909–2915. [PubMed] [Google Scholar]
  24. Owen-Schaub L. B., Zhang W., Cusack J. C., Angelo L. S., Santee S. M., Fujiwara T., Roth J. A., Deisseroth A. B., Zhang W. W., Kruzel E. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol. 1995 Jun;15(6):3032–3040. doi: 10.1128/mcb.15.6.3032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Sheard M. A., Vojtesek B., Janakova L., Kovarik J., Zaloudik J. Up-regulation of Fas (CD95) in human p53wild-type cancer cells treated with ionizing radiation. Int J Cancer. 1997 Nov 27;73(5):757–762. doi: 10.1002/(sici)1097-0215(19971127)73:5<757::aid-ijc24>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  26. Suda T., Okazaki T., Naito Y., Yokota T., Arai N., Ozaki S., Nakao K., Nagata S. Expression of the Fas ligand in cells of T cell lineage. J Immunol. 1995 Apr 15;154(8):3806–3813. [PubMed] [Google Scholar]
  27. Williams B. A., Makrigiannis A. P., Blay J., Hoskin D. W. Treatment of the P815 murine mastocytoma with cisplatin or etoposide up-regulates cell-surface Fas (CD95) expression and increases sensitivity to anti-Fas antibody-mediated cytotoxicity and to lysis by anti-CD3-activated killer-T cells. Int J Cancer. 1997 Nov 4;73(3):416–423. doi: 10.1002/(sici)1097-0215(19971104)73:3<416::aid-ijc17>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  28. Zhan Q., Fan S., Bae I., Guillouf C., Liebermann D. A., O'Connor P. M., Fornace A. J., Jr Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene. 1994 Dec;9(12):3743–3751. [PubMed] [Google Scholar]
  29. von Reyher U., Sträter J., Kittstein W., Gschwendt M., Krammer P. H., Möller P. Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Res. 1998 Feb 1;58(3):526–534. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES